Follow Boston Scientific to never miss an important update.
On November 17, the board approved the annual bonus and stock performance plans for 2027. These plans decide how much extra cash and stock executives and certain employees receive based on the company hitting specific goals for sales and adjusted earnings per share. The structure remains consistent with prior years, allowing for payouts between 0 and 225 percent of an individual's target. While these filings are routine, they confirm that the company is sticking to its existing compensation strategy as it moves into the new year.
Source: 8-K filing
Boston Scientific is partnering with Blackstone to develop the VITALYST system, a small pump designed to help the heart move blood to the brain and other organs during medical emergencies. Blackstone will provide about 455 million dollars to cover the costs of bringing this device to market.
This is a smart way for the company to expand its heart-care lineup without spending its own cash. By letting an outside firm fund the development, Boston Scientific can keep its focus on recovering from a recent cyberattack while still building out a new product that could eventually add to its sales.
Source: Business Wire
The SIMPLAAFY study showed that patients who received the Watchman device, which helps prevent strokes by closing off a small part of the heart, did just as well on a single drug as those on a more complex two-drug plan. This simpler approach met its main goals for safety and effectiveness over six months.
This is a win for the company because a simpler drug routine makes the procedure more attractive to patients and doctors. Reducing the need for heavy blood thinners after surgery lowers the risk of bleeding, which helps Boston Scientific protect its lead in the stroke-prevention market.
Source: PRNewsWire
TD Cowen lowered its rating on the medical device maker from Buy to Hold on Friday. This follows a similar move by Jefferies and comes after the company lowered its full-year sales targets due to a slower-than-expected recovery from an August cyberattack.
While the company's heart surgery products remain in high demand, analysts are concerned that the technical and operational fallout from the hack is lasting longer than first thought. The average price target across all firms now sits at $55, which is still well above the current price of about $42.
Source: TD Cowen
After Boston Scientific reported its October results, we updated our fair value and cut our quality score to 3.3. We lowered our growth projections for the cardiovascular segment and the Asia-Pacific region, where sales turned negative over the past three months. We added a specific risk for how vulnerable the company's digital infrastructure is to operational disruptions. We also added two new things to what we track: the progress of the internal restructuring plan and the leadership transition within the medical surgery division.
Management consistently sets a conservative bar and clears it by a few cents every quarter. This reliable pattern makes their forecasts easy to trust, even during difficult operational stretches.
| Expectation | |
|---|---|
| EPS | $0.78 |
| Revenue | $5.18B |
Follow Boston Scientific to get the latest and most important updates.
Follow BSX